Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p63 shRNA is a short hairpin RNA (shRNA) designed to silence the expression of the p63 protein, specifically the ΔNp63α isoform, which is often overexpressed in various cancers including pancreatic ductal adenocarcinoma (PDAC). By utilizing the RNA interference (RNAi) pathway, the shRNA mediates the degradation of p63 mRNA, leading to reduced protein levels. In preclinical studies, knockdown of p63 using shRNA has been shown to inhibit tumor cell proliferation, migration, and invasiveness, suggesting that targeting the p63 pathway may be a viable therapeutic strategy for treating aggressive cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on p63 shRNA.